Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

Global medicines expenditure is forecast to reach USD $1.4 trillion annually by 2020 [1], an increase of approximately 30% from 2015 levels. Given this upward pressure on healthcare budgets, balancing total spend on pharmaceuticals with the imperative to provide timely access to new medicines will be a critical priority for policy-makers. In the major European markets (France, Italy, Germany, Spain and the UK), payers, including both statutory organisations with delegated authority and compulsory/statutory health insurers, are expected to be at the forefront of finding solutions for optimising expenditure on medicines.

Source: Health Policy - March 8, 2018 Category: Health Management Authors: William C.N. Dunlop, Alexandra Staufer, Pierre Levy, Guy J. Edwards Source Type: research